ClinicalTrials.gg
RecruitingNCT07342582Updated Nov 13, 2026

The Rhinovirus Hospitalization and Investigation of Nasal-airway Omics (RHINO) Study

An observational study in Rhinovirus, sponsored by University of Wisconsin, Madison. Recruiting at 1 site in United States. Open to participants aged Up to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by University of Wisconsin, Madison · Observational

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Nov 13, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
670
Ages
Up to 17 Years
Sex
All
01

Study summary

The goal of this study is to determine the burden of Rhinoviruses (RVs) as a cause of acute, severe, respiratory illnesses leading to hospitalization. A community cohort of 120 children between 12 and 36 months of age will be enrolled in the first year of the study and followed (when well and sick) for 36 months to identify the circulating RVs and provide samples to establish a host nasal transcriptome differentiating clinical from subclinical RV infections. A hospitalized cohort of 450 infants and children will be enrolled during years 1 through 3 of the study and followed for the duration of their hospitalization to investigate the findings of the community cohort. An additional 100 healthy children aged 5-17.5 years will be enrolled for age-match comparison with the older hospitalized cohort.

Read the detailed description

Aim 1: Involves the prospective creation of a cohort of generally healthy children 12 to 36 months to be followed longitudinally for 36 months in an observational study. To determine the frequency of virus infection with RV and other respiratory viruses, children will have two swabs of the nasal mucosa performed whenever they develop an acute respiratory illness (upper respiratory symptoms lasting more than 24 hours) and four times a year for surveillance. One swab will be of the anterior nose and will be used for identification of viruses, and a second mid-turbinate swab will be used for host transcriptomics. This will allow the investigators to create many samples from both symptomatic and asymptomatic infections. The samples will be used to develop a host signature to discriminate symptomatic and asymptomatic infection.

Aim 2a: Involves the evaluation of generally healthy children hospitalized at AFCH with acute, lower respiratory tract infections including bronchiolitis, asthma, acute hypoxemic respiratory failure and community acquired pneumonia. There will also be the evaluation of infants less than 6 months of age who may become ill with an RV syndrome. These children will be evaluated with two nasal swabs as above. This allows the identification of children infected with RV and other respiratory viruses. Application of the host signature developed in Aim 1 will determine the actual proportion of those children who are infected with RV whose illness (clinical symptoms) is caused by RV.

Aim 2b: Involves the prospective creation of a cohort of generally healthy children 5 to 17.5 years old to be sampled on an as-needed basis to serve as age- and season-matched controls for the Hospitalized Group. To determine the frequency of virus infection with RV and other respiratory viruses, 2 healthy children will provide a single swab of the nasal mucosa within 2 weeks of each hospitalized participant who is 5-17.5 years of age. The one swab will be of the anterior nose and will be used for identification of viruses. Age matching will occur within 3 groups:

  • Ages 5-8 years old: n=50
  • Ages 9-13 years old: n=30
  • Ages 14-17.5 years old: n=20

Aim 3: Use parallel bulk and single cell RNA sequencing (scRNA-seq) to identify targetable processes of acute, severe LRT caused by RV. The investigators hypothesize that integrated bulk RNA-sequencing and scRNA-seq will identify immune/inflammatory defects and targets for intervention. Bulk and scRNA-seq on respiratory samples from well-characterized patients with severe RV disease will be performed to test this hypothesis and to compare samples obtained from those with non-severe disease.

02

Conditions studied

  • Rhinovirus

Keywords

  • infants
  • children
  • symptomatic
  • asymptomatic
  • lower respiratory tract infection
03

In context

Lead sponsor

University of Wisconsin, Madison is the lead sponsor of 1,190 studies on the registry; 181 are open to participants now.

Of its 157 completed or terminated interventional studies of FDA-regulated products, 118 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Nov 13, 2026. See what changed

Ages eligible
Up to 17 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Aim 1: Generally healthy male and female children 12 to 36 months of age living in Dane County and surrounding areas representative of the general demographics of the county.

Aim 2a: Hospitalized male and female children between newborn and 17.5 years of age with acute onset lower respiratory tract infections. These children will span all demographic and socioeconomic groups.

Aim 2b: Generally healthy male and female children 5 to 17.5 years of age living in Dane County and surrounding areas representative of the general demographics of the county.

Eligibility criteria

Inclusion Criteria (Aim 1 and Aim 2b Community Groups):

  • Parent/legal guardian is willing and able to provide in English.
  • Willing to comply with all study procedures and be available for the duration of the study.
  • Younger Community Group: Generally healthy children 12 to 36 months of age at the time of enrollment
  • Older Community Group: Generally healthy children 5 to 17.5 years of age at the time of enrollment.
  • Current patient within primary care system at UW Health

Inclusion Criteria (Aim 2a: Hospitalized Group):

  • Parent/legal guardian is willing and able to provide informed consent in English.
  • Admitted to American Family Children's Hospital (AFCH) within the past 24 hours or have been assigned an admission-related status (including "Admit Probable" or "IP Bed Requested") that reflects an expected inpatient admission.
  • Children under 17.5 years of age at the time of enrollment
  • Has a diagnosis of bronchiolitis, asthma exacerbation, acute hypoxemic respiratory failure or community acquired pneumonia (CAP) OR is an infant less than 6 months of age with fever greater than 38 degrees Celsius within 24 hours of hospital admission

Exclusion Criteria (all participants):

  • Congenital or currently acquired condition or medications (e.g., congenital immunodeficiency, Leukemia, Lupus)
  • Congenital anomalies that might alter frequency of infection (e.g., unrepaired cleft palate, bronchial cyst, pulmonary sequestration)
  • Presence of tracheostomy or gastrostomy tube
  • Previously enrolled a different group in the study
  • Other child in the same household already enrolled in the study
  • Not suitable for study participation due to other reasons at the discretion of the investigators.

Exclusion Criteria (Aim 1: Community Group Only):

  • History of chronic pulmonary diseases (e.g., asthma, cystic fibrosis, bronchopulmonary dysplasia (BPD)) (Note: asthma IS exclusionary), reactive airway disease within the Older Community Group is not exclusionary unless they have a maintenance inhaler.
  • Acute upper respiratory symptoms within the past week (7 days) at the time of enrollment

Exclusion Criteria (Aim 2: Hospitalized Group Only):

  • History of chronic pulmonary diseases, excluding asthma (e.g., cystic fibrosis, bronchopulmonary dysplasia (BPD)) (Note: asthma is NOT exclusionary)
  • A positive test for any other respiratory virus other than RV within the 48 hours prior to and including admission documented at the time of consent. (Note: Negative for rhinovirus is not exclusionary).
  • Non-respiratory infection at the time of admission (e.g. Bacteremia) (Note: UTI, Osteomyelitis, Otitis media, and MRSA colonization is not exclusionary.)
  • Uncontrolled and/or profound neurologic disease, as determined by the investigator or designee at time of admission, considering factors such as uncontrolled seizures, inability to ambulate, inability to communicate verbally, or dependence on a gastrostomy tube (G-tube) or ventilatory assistance (e.g., positive pressure ventilation) (e.g., cerebral palsy, genetic neurologic diseases).

Exclusion Criteria (less than 5 years old only (All participants in Aim 1 and some participants in Aim 2a):

  • Born prematurely, less than 32 weeks 0 days gestational age
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
670 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Younger Community Cohort (12-36 months of age)

    Quarterly Surveillance Nasal Swabs and Nasal Swabs targeted around respiratory symptoms for up to 36 months of age, participants will provide one anterior and one mid-turbinate nasal swab sample

    Diagnostic Test: Nasal Swab Healthy Surveillance · Diagnostic Test: Nasal Swab Sick Samples · Other: Sick Follow-up Survey

  • Hospitalized Cohort of Infants and Children

    Generally healthy infants and children hospitalized for respiratory illness will provide one anterior and one mid-turbinate nasal swab sample

    Diagnostic Test: Nasal Swab Hospitalized Cohort · Other: Procedural Comfort or Care

  • Older Community Cohort (5 to 17.5 years of age)

    Age-matched controls for older children in the Hospitalized Group, will be called upon as needed based on enrollment of hospitalized patients

    Other: Older Cohort Control Group

Interventions

  • Diagnostic testNasal Swab Healthy Surveillance

    Families will be asked to collect nasal swabs from their children during specified surveillance months (February, April, September, and December). Caregivers will be instructed to only collect surveillance samples during these months if and when children have been free of respiratory symptoms for at least two weeks prior to sampling. Caregiver surveys are part of quarterly surveillance.

  • Diagnostic testNasal Swab Sick Samples

    Caregivers will be instructed to watch for respiratory symptoms and collect nasal swabs 24-48 hours after symptom onset. Caregiver surveys are part of sick sample collection

  • Diagnostic testNasal Swab Hospitalized Cohort

    2 nasal swabs collected upon consent, one anterior and one mid-turbinate

  • OtherSick Follow-up Survey

    Caregivers are surveyed 7-13 days after sick sample collection

  • OtherOlder Cohort Control Group

    Participants will be enrolled as needed based on enrollment of hospitalized patients

  • OtherProcedural Comfort or Care

    For hospitalized participants who opt to induce sputum, 3 medications will be used to obtain the sample, albuterol sulfate solution and hypertonic saline (3% solution) administered via nebulizer and and lidocaine spray (4% solution) via atomizer to the nose. For hospitalized participants with pneumonia who opt for research blood draw or induced sputum, optional administration of oral sucrose (Sweet-Ease) may occur at the discretion of the treating provider.

    Also known as: Albuterol sulfate solution, Hypertonic saline, Lidocaine spray, Sweet-Ease

06

What researchers measure

Primary outcomes

  1. Aim 1: Summary of Rhinovirus Types Identified in Community Cohort

    To test study hypotheses, the study team will identify the circulating RV types in symptomatic and asymptomatic children.

    Time frame: data collected up to 36 months

  2. Aim 1: Unique Nasal Transcriptomic Signature of Clinical Rhinovirus Infections

    Time frame: data collected up to 36 months

Secondary outcomes

  1. Aim 2: Summary of Rhinovirus Types Identified in lower respiratory tract (LRT) infections and upper respiratory tract infections (URI), Reported as Percent in Common

    To test the hypothesis that there will be an 80 percent overlap between RV types causing acute LRT and URI, investigators will compare all RV types identified in age-matched hospitalized and ambulatory children.

    Time frame: data collected up to 36 months

  2. Aim 2: Proportion of Hospitalized Cohort with lower respiratory infections attributable to Rhinovirus

    The investigators will use host nasal transcriptomics derived from symptomatic and asymptomatic children with RV infection to determine the proportion of age-matched hospitalized LRT infections actually attributable to RV.

    Time frame: data collected up to 36 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — This study will comply with the NIH Genomic Data Sharing Policy, which applies to all NIH-funded research that generates large-scale human or non-human genomic data, as well as the use of these data for subsequent research. Large-scale data include genome-wide association studies (GWAS), single nucleotide polymorphisms (SNP) arrays, and genome sequence, transcriptomic, epigenomic, and gene expression data.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data from this study may be requested from other researchers 3 years after the completion of the primary endpoint by contacting the study team at UW-Madison.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2026 (actual). Primary completion is estimated for May 2030, 45 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2026
First posted
Jan 15, 2026
StartActual
Aug 4, 2026
Primary completionEst.
May 2030
CompletionEst.
May 2030
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
3 criteria edited, 2 added, 2 removed
What changed in the criteria
  • EditedAdmitted to American Family Children's Hospital (AFCH) within the past 24 hours or have been assigned an admission-related status (including "Admit Probable" or "IP Bed Requested") that reflects an expected inpatient admission.
  • EditedHistory of chronic pulmonary diseases (e.g., asthma, cystic fibrosis, bronchopulmonary dysplasia (BPD)) (Note: asthma IS exclusionary), reactive airway disease within the Older Community Group is not exclusionary unless they have a maintenance inhaler.
  • EditedA positive test for any other respiratory virus other than RV within the 48 hours prior to and including admission documented at the time of consent. (Note: Negative for rhinovirus is not exclusionary).
  • RemovedNon-respiratory infection at the time of admission
  • RemovedNeurologic disease (for example, cerebral palsy, genetic neurologic diseases, seizure disorder)
  • AddedNon-respiratory infection at the time of admission (e.g. Bacteremia) (Note: UTI, Osteomyelitis, Otitis media, and MRSA colonization is not exclusionary.)
  • AddedUncontrolled and/or profound neurologic disease, as determined by the investigator or designee at time of admission, considering factors such as uncontrolled seizures, inability to ambulate, inability to communicate verbally, or dependence on a gastrostomy tube (G-tube) or ventilatory assistance (e.g., positive pressure ventilation) (e.g., cerebral palsy, genetic neurologic diseases).
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Eligibility 3 criteria edited, 2 added, 2 removed
    What changed in the criteria
    • EditedAdmitted to American Family Children's Hospital (AFCH) within the past 24 hours or have been assigned an admission-related status (including "Admit Probable" or "IP Bed Requested") that reflects an expected inpatient admission.
    • EditedHistory of chronic pulmonary diseases (e.g., asthma, cystic fibrosis, bronchopulmonary dysplasia (BPD)) (Note: asthma IS exclusionary), reactive airway disease within the Older Community Group is not exclusionary unless they have a maintenance inhaler.
    • EditedA positive test for any other respiratory virus other than RV within the 48 hours prior to and including admission documented at the time of consent. (Note: Negative for rhinovirus is not exclusionary).
    • RemovedNon-respiratory infection at the time of admission
    • RemovedNeurologic disease (for example, cerebral palsy, genetic neurologic diseases, seizure disorder)
    • AddedNon-respiratory infection at the time of admission (e.g. Bacteremia) (Note: UTI, Osteomyelitis, Otitis media, and MRSA colonization is not exclusionary.)
    • AddedUncontrolled and/or profound neurologic disease, as determined by the investigator or designee at time of admission, considering factors such as uncontrolled seizures, inability to ambulate, inability to communicate verbally, or dependence on a gastrostomy tube (G-tube) or ventilatory assistance (e.g., positive pressure ventilation) (e.g., cerebral palsy, genetic neurologic diseases).
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07342582
Responsible party
Sponsor
First posted
Jan 15, 2026
Start date
Aug 4, 2026
Primary completion
May 2030 (estimated)
Completion
May 2030 (estimated)
Last update
Nov 13, 2026

Study contacts

Research Nurses
Contact
reserachnurses@pediatrics.wisc.edu
608-228-4940
Ellen R Wald, MD
principal investigator · UW School of Medicine and Public Health

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion